Exact Sciences Corporation

EXASintermediary

Exact Sciences is a molecular diagnostics company focused on cancer screening and precision oncology. Its Cologuard test has become the leading non-invasive colorectal cancer screening tool, and its multi-cancer early detection test aims to transform cancer diagnosis.

⇄ Compare

Productos e Ingresos

Participación de Ingresos por Producto

Desglose de Ingresos ($2.8B)

Datos estáticos (cargando finanzas en tiempo real…)

Screening (Cologuard) (55%)

Precision Oncology (Oncotype DX) (35%)

Other / Pipeline (10%)

Composición de segmentos y clientes principales

Detalles del producto

Cologuard (Colorectal Cancer)45%

Non-invasive stool DNA test for colorectal cancer screening

Oncotype DX (Breast Cancer)30%

Genomic test predicting breast cancer recurrence risk

Multi-Cancer Early Detection (MCED)10%

Blood-based test detecting multiple cancer types from a single draw

Relaciones en la Cadena de Suministro

Socios

Pfizer Inc.

Cancer screening combined with pharma treatment

Impacto: Low — co-marketing exploration

Eli Lilly and Company

Companion diagnostics for oncology drugs

Impacto: Low — diagnostic partnerships

Regeneron Pharmaceuticals

Genomic profiling for antibody therapies

Impacto: Low

Contexto macro y de mercado

제약 / 바이오Noticias del sector

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Próximos catalizadores

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Últimas noticias

Cargando noticias...

Análisis IA

Haz clic en "Obtener Análisis IA" para un análisis de cadena de suministro de Exact Sciences Corporation impulsado por IA.

Información de la Empresa

Sede Central

Madison, Wisconsin, USA

Fundación

1995

Empleados

7,200+

Sitio Web

exactsciences.com

Estado del sector — 제약 / 바이오

Noticias del sector